Small companies with a one-drug pipeline and a finite patent runway have no unfair advantage over anyone to monetize the drug.
They have the projected cash flow off that runway. That’s it.
There is NO way a small company can monetize that runway anywhere near as efficiently as a Big Pharma company — they already have the apparatus to sell the drug and the expertise to maximize footprint as fast as possible. Margins simply go way up, and there are no mitigating variables.
This was probably the simplest analysis Sarissa ever performed. This company is worth $x on a DCF basis in its current, maximally inefficient configuration, and $2x simply having its single drug acquired.
There’s nothing AMRN can do on its own that a big company can’t do way better. That’s why Denner bought into this turd. That’s the obvious fact he saw.
JR. Because of the exclusivity clock Denner will work as fast as possible to cut costs and dress up the Co for sale … once / if he has reimbursement decisions in the remaining large EU markets
MDCO all over again … hopefully.
If France agrees to reimburse I’ll probably buy in even if it’s at a higher price … especially if Denner has BOD influence
As far as I can tell, the only thing anyone knows for sure is that Amarin has surrendered control of their narrative to an external entity. So far, there has been a lot of wasted speculation on what Sarissa would do. How could anyone be surprised when yesterday they did exactly what they said they were going to do? Yet….smh.
Here’s what they said they are going to do next:
“Sarissa has submitted notice to Amarin under UK law to call a special meeting of shareholders to add 7 directors to the board and to remove Chairman Per Wold-Olsen from the board.”
News 
Market Data 
Discover 
